These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31611695)

  • 1. Predicting HLA class II antigen presentation through integrated deep learning.
    Chen B; Khodadoust MS; Olsson N; Wagar LE; Fast E; Liu CL; Muftuoglu Y; Sworder BJ; Diehn M; Levy R; Davis MM; Elias JE; Altman RB; Alizadeh AA
    Nat Biotechnol; 2019 Nov; 37(11):1332-1343. PubMed ID: 31611695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLAIImaster: a deep learning method with adaptive domain knowledge predicts HLA II neoepitope immunogenic responses.
    Yang Q; Xu L; Dong W; Li X; Wang K; Dong S; Zhang X; Yang T; Jiang F; Zhang B; Luo G; Gao X; Wang G
    Brief Bioinform; 2024 May; 25(4):. PubMed ID: 38920343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of a Predictive Cleavage Motif for Eluted Major Histocompatibility Complex Class II Ligands.
    Paul S; Karosiene E; Dhanda SK; Jurtz V; Edwards L; Nielsen M; Sette A; Peters B
    Front Immunol; 2018; 9():1795. PubMed ID: 30127785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DeepNetBim: deep learning model for predicting HLA-epitope interactions based on network analysis by harnessing binding and immunogenicity information.
    Yang X; Zhao L; Wei F; Li J
    BMC Bioinformatics; 2021 May; 22(1):231. PubMed ID: 33952199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLimmuno2: predicting MHC class II antigen immunogenicity through transfer learning.
    Wang G; Wu T; Ning W; Diao K; Sun X; Wang J; Wu C; Chen J; Xu D; Liu XS
    Brief Bioinform; 2023 May; 24(3):. PubMed ID: 36960769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integral Use of Immunopeptidomics and Immunoinformatics for the Characterization of Antigen Presentation and Rational Identification of BoLA-DR-Presented Peptides and Epitopes.
    Fisch A; Reynisson B; Benedictus L; Nicastri A; Vasoya D; Morrison I; Buus S; Ferreira BR; Kinney Ferreira de Miranda Santos I; Ternette N; Connelley T; Nielsen M
    J Immunol; 2021 May; 206(10):2489-2497. PubMed ID: 33789985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of Neoantigen Identification Through Convolution Neural Network.
    Hao Q; Wei P; Shu Y; Zhang YG; Xu H; Zhao JN
    Front Immunol; 2021; 12():682103. PubMed ID: 34113354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.
    Schneidman-Duhovny D; Khuri N; Dong GQ; Winter MB; Shifrut E; Friedman N; Craik CS; Pratt KP; Paz P; Aswad F; Sali A
    PLoS One; 2018; 13(11):e0206654. PubMed ID: 30399156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RBM-MHC: A Semi-Supervised Machine-Learning Method for Sample-Specific Prediction of Antigen Presentation by HLA-I Alleles.
    Bravi B; Tubiana J; Cocco S; Monasson R; Mora T; Walczak AM
    Cell Syst; 2021 Feb; 12(2):195-202.e9. PubMed ID: 33338400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MATHLA: a robust framework for HLA-peptide binding prediction integrating bidirectional LSTM and multiple head attention mechanism.
    Ye Y; Wang J; Xu Y; Wang Y; Pan Y; Song Q; Liu X; Wan J
    BMC Bioinformatics; 2021 Jan; 22(1):7. PubMed ID: 33407098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules.
    Zhang L; Chen Y; Wong HS; Zhou S; Mamitsuka H; Zhu S
    PLoS One; 2012; 7(2):e30483. PubMed ID: 22383964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
    Racle J; Michaux J; Rockinger GA; Arnaud M; Bobisse S; Chong C; Guillaume P; Coukos G; Harari A; Jandus C; Bassani-Sternberg M; Gfeller D
    Nat Biotechnol; 2019 Nov; 37(11):1283-1286. PubMed ID: 31611696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.
    Hattotuwagama CK; Doytchinova IA; Flower DR
    Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple pan-specific RNN model for predicting HLA-II binding peptides.
    Heng Y; Kuang Z; Xie W; Lan H; Huang S; Chen L; Shi T; Xu L; Pan X; Mei H
    Mol Immunol; 2021 Nov; 139():177-183. PubMed ID: 34555693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data.
    Garde C; Ramarathinam SH; Jappe EC; Nielsen M; Kringelum JV; Trolle T; Purcell AW
    Immunogenetics; 2019 Jul; 71(7):445-454. PubMed ID: 31183519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
    Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
    Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
    Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C
    Front Immunol; 2018; 9():872. PubMed ID: 29774024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.